Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents Press Releases | 10 September 2021 PR-Servier-Neurochlore-Bumetanide Phase 3 ResultsTélécharger Projects supported Bumetanide responders Treating brain tumors NKCC1 inhibitors Fundamental Research Clinical trials Contact Press Releases Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents 10 September 2021
